Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NDL013
MIFTS: 48

Nodular Regenerative Hyperplasia

Categories: Liver diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Nodular Regenerative Hyperplasia

About this section

MalaCards integrated aliases for Nodular Regenerative Hyperplasia:

Name: Nodular Regenerative Hyperplasia 53 72
Nodular Regenerative Hyperplasia of the Liver 53 59
Non-Cirrhotic Nodulation 53 59
Non-Cirrhotic Nodular Transformation 53
Miliary Hepatocellular Adenomatosis 53
Non-Cirrhotic Portal Hypertension 53
Nodular Hyperplasia 72

Characteristics:

Orphanet epidemiological data:

59
nodular regenerative hyperplasia of the liver
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Liver diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare hepatic diseases


External Ids:

ICD10 via Orphanet 34 K76.8
Orphanet 59 ORPHA48372
UMLS 72 C0020510 C4048264
Sources

Summaries for Nodular Regenerative Hyperplasia

About this section
NIH Rare Diseases : 53 Nodular regenerative hyperplasia (NRH) is a rare liver disease in which normal liver tissue transforms into multiple, small clusters (nodules) of replicating liver cells (regenerating hepatocytes). It can develop in people of all ages but is more common in older adults. NRH often does not cause signs or symptoms (so is likely underdiagnosed), but in some people, it leads to a type of portal hypertension called non-cirrhotic portal hypertension (NCPH). NCPH refers to abnormally high blood pressure in the portal vein (the vein that carries blood from the intestine to the liver) that is not caused by cirrhosis (scarring of liver tissue that impairs its function). NCPH typically is less severe than portal hypertension caused by cirrhosis. Symptoms of portal hypertension may include fatigue, edema, itching, jaundice, and abdominal discomfort or swelling due to fluid build-up (ascites). Complications that may develop include bleeding esophageal varices and an enlarged and overactive spleen (hypersplenism). Liver function in most people with NRH remains normal (even in those who develop NCPH), and liver failure in people with NRH and NCPH is rare. The cause of NRH is not well-understood. It is thought that the liver's blood vessels somehow become damaged or inflamed, impairing blood flow to parts of the liver. This in turn may cause cells in adjacent parts to "overcompensate" and replicate more than they should, leading to NRH. While some people with NRH have no known underlying health problems, NRH is often associated with rheumatic, autoimmune, hematologic (blood-related), and myeloproliferative disorders; chronic or recurrent infections; immune deficiency; or exposure to certain medications or toxins. NRH may be diagnosed based on signs and symptoms (when present), liver function tests (which usually are normal), medical history (including drug or toxin exposure), imaging studies, and liver biopsy (to rule out cirrhosis). Treatment for people with NCPH may involve starting medications to prevent or treat bleeding esophageal varices, stopping medications associated with NCPH, and treating underlying health conditions associated with NCPH. The long-term outlook for people with NRH depends on whether an underlying health problem is present and whether NCPH and its complications develop (which cannot be predicted). A small proportion of people eventually need a liver transplant.

MalaCards based summary : Nodular Regenerative Hyperplasia, also known as nodular regenerative hyperplasia of the liver, is related to alagille syndrome 1 and portal hypertension. An important gene associated with Nodular Regenerative Hyperplasia is NOTCH1 (Notch Receptor 1), and among its related pathways/superpathways are Th17 cell differentiation and Wnt / Hedgehog / Notch. The drugs Caffeine and Calcium have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow, and related phenotypes are portal hypertension and abnormality of the hepatic vasculature

Wikipedia : 75 Nodular regenerative hyperplasia is a form of liver hyperplasia associated with portal hypertension.... more...

Sources

Related Diseases for Nodular Regenerative Hyperplasia

About this section

Diseases related to Nodular Regenerative Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 alagille syndrome 1 29.4 NOTCH2 NOTCH1 JAG1
2 portal hypertension 11.0
3 varicose veins 10.7
4 esophageal varix 10.6
5 splenomegaly 10.6
6 liver cirrhosis 10.6
7 felty syndrome 10.6
8 autoimmune disease 10.6
9 inflammatory bowel disease 10.5
10 primary biliary cirrhosis 10.5
11 primary biliary cholangitis 10.5
12 cholestasis 10.5
13 liver disease 10.5
14 hepatoportal sclerosis 10.5
15 immune deficiency disease 10.5
16 common variable immunodeficiency 10.4
17 pulmonary hypertension 10.4
18 vascular disease 10.4
19 encephalopathy 10.4
20 hepatocellular carcinoma 10.4
21 systemic lupus erythematosus 10.4
22 hepatic coma 10.4
23 hepatic encephalopathy 10.4
24 hypersplenism 10.4
25 lupus erythematosus 10.4
26 peliosis hepatis 10.4
27 celiac disease 1 10.3
28 crest syndrome 10.3
29 hepatic veno-occlusive disease 10.3
30 portal vein thrombosis 10.3
31 telangiectasis 10.3
32 adenoma 10.3
33 scleroderma, familial progressive 10.3
34 budd-chiari syndrome 10.3
35 thrombocytopenia 10.3
36 glomerulonephritis 10.3
37 antiphospholipid syndrome 10.3
38 vasculitis 10.3
39 crohn's disease 10.3
40 polyarteritis nodosa 10.3
41 banti's syndrome 10.3
42 thrombophilia due to thrombin defect 10.2
43 splenic artery aneurysm 10.2
44 myeloproliferative neoplasm 10.2
45 systemic mastocytosis 10.2
46 mastocytosis 10.2
47 congenital hepatic fibrosis 10.2
48 pulmonary hypertension, primary, 1 10.2
49 rheumatoid arthritis 10.2
50 myeloma, multiple 10.2

Graphical network of the top 20 diseases related to Nodular Regenerative Hyperplasia:



Diseases related to Nodular Regenerative Hyperplasia
Sources

Symptoms & Phenotypes for Nodular Regenerative Hyperplasia

About this section

Human phenotypes related to Nodular Regenerative Hyperplasia:

59 32
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 portal hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0001409
2 abnormality of the hepatic vasculature 59 Very frequent (99-80%)

MGI Mouse Phenotypes related to Nodular Regenerative Hyperplasia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.13 EFNB2 F3 GFER ITPA JAG1 NOTCH1
2 hematopoietic system MP:0005397 10.06 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
3 cellular MP:0005384 10.05 EFNB2 F3 GFER ITPA JAG1 NOTCH1
4 mortality/aging MP:0010768 10.02 EFNB2 F3 GFER ITPA JAG1 NOTCH1
5 cardiovascular system MP:0005385 10 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
6 homeostasis/metabolism MP:0005376 9.98 EFNB2 F3 GFER JAG1 NOTCH1 NOTCH2
7 embryo MP:0005380 9.89 EFNB2 F3 JAG1 NOTCH1 NOTCH2
8 integument MP:0010771 9.88 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
9 muscle MP:0005369 9.8 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
10 neoplasm MP:0002006 9.56 F3 GFER NOTCH1 NOTCH2
11 normal MP:0002873 9.55 EFNB2 F3 JAG1 NOTCH1 NOTCH2
12 respiratory system MP:0005388 9.35 EFNB2 F3 ITPA NOTCH1 NOTCH2
13 vision/eye MP:0005391 9.02 EFNB2 F3 JAG1 NOTCH1 NOTCH2
Sources

Drugs & Therapeutics for Nodular Regenerative Hyperplasia

About this section

Drugs for Nodular Regenerative Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4 58-08-2 2519
2
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
3 Analgesics Phase 4
4 Mesalamine Phase 4 89-57-6
5 Analgesics, Non-Narcotic Phase 4
6 Anti-Inflammatory Agents, Non-Steroidal Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Calcium, Dietary Phase 4
9 Calcium Supplement Phase 4
10
Propranolol Approved, Investigational Phase 3 525-66-6 4946
11
Apixaban Approved Phase 3 503612-47-3 10182969
12
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
13 Neurotransmitter Agents Phase 3
14 Antihypertensive Agents Phase 3
15 Adrenergic beta-Antagonists Phase 3
16 Adrenergic Antagonists Phase 3
17 Adrenergic Agents Phase 3
18 Vasodilator Agents Phase 3
19 Anti-Arrhythmia Agents Phase 3
20 Liver Extracts Phase 3
21
protease inhibitors Phase 3
22 HIV Protease Inhibitors Phase 3
23 Serine Proteinase Inhibitors Phase 3
24 Antithrombins Phase 3
25 Antithrombin III Phase 3
26 Factor Xa Inhibitors Phase 3
27 Anticoagulants Phase 3
28
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
29
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
30
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
31 Pharmaceutical Solutions Phase 1, Phase 2
32 Antirheumatic Agents Phase 1, Phase 2
33 Alkylating Agents Phase 1, Phase 2
34 Immunologic Factors Phase 1, Phase 2
35 Antibodies Phase 1, Phase 2
36 Immunosuppressive Agents Phase 1, Phase 2
37 Immunoglobulins Phase 1, Phase 2
38 Antibodies, Monoclonal Phase 1, Phase 2
39 Antineoplastic Agents, Alkylating Phase 1, Phase 2
40
Norethindrone Approved 68-22-4 6230
41
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
42
Polyestradiol phosphate Approved 28014-46-2
43
Etomidate Approved 33125-97-2 36339 667484
44
Epinephrine Approved, Vet_approved 51-43-4 5816
45
Racepinephrine Approved 329-65-7 838
46
Ifosfamide Approved 3778-73-2 3690
47
Vincristine Approved, Investigational 57-22-7, 2068-78-2 5978
48
Dactinomycin Approved, Investigational 50-76-0 457193 2019
49
Doxorubicin Approved, Investigational 23214-92-8 31703
50
Choline Approved, Nutraceutical 62-49-7 305

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL. Unknown status NCT01789294 Phase 4 Mesalamine
2 Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial Completed NCT01000779 Phase 3 Propranolol
3 Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Recruiting NCT04007289 Phase 3 Apixaban;Placebo
4 Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® in Healthy Volunteers and in Patients With Liver Disease Completed NCT01420211 Phase 1, Phase 2 Primovist® 0,25 mmol/ml solution for injection
5 High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease Recruiting NCT02629120 Phase 1, Phase 2 Campath;Busulfan;cyclophosphamide
6 Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection Unknown status NCT03208192
7 Evaluation of Gastroesophageal Varices in Cirrhotic and Non-cirrhotic Patients With Portal Hypertension by Transnasal Endoscopy. Unknown status NCT02767206
8 Prevalence of Mutations of Glucocorticoid Receptors in Bilateral Adrenal Hyperplasia Unknown status NCT02810496
9 Contrast Enhanced Ultrasound for the Evaluation of Focal Liver Lesions - a Multi-center Study on the Usefulness in the Clinical Practice Unknown status NCT01329458
10 Feasibility of Electromagnetic Acoustic Imaging of Liver Tumours - A Pilot Study Unknown status NCT02827786
11 Diagnostic Accuracy of 18F-FluoroethylCholine Positron Emission Tomography for Hepatocellular Carcinoma Unknown status NCT02238769
12 Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy Completed NCT00825617 Hormone replacement therapy
13 Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension Completed NCT02635815
14 Quantitative Real-time Ultrasound Elastography (Shear Wave Elastography - SWEâ„¢) for Characterisation of Liver Tumors Completed NCT02156700
15 Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI) in Non-Cirrhotic Patients - A Double Blind International Multicenter Study Completed NCT01234701
16 Evaluation of Sickle Cell Liver Disease Completed NCT01950429
17 Characterization of Liver Masses With Contrast Enhanced Ultrasound (CEUS): A Comparison With Standard Institutional Contrast Enhanced CT (CECT) or MR Scan (CEMRI) Completed NCT00828607
18 Functional Imaging With 11C-Metomidate Positron Emission Tomography Versus Adrenal Vein Sampling in Differential Diagnosis of Unilateral and Bilateral Aldosterone Secretion in Primary Aldosteronism Completed NCT01567111
19 "The Fingerprint: Spoke-wheel Sign" of Focal Nodular Hyperplasia: Assessment of Novel Ultrasound Approach Using Superb Microvascular Imaging Technique Recruiting NCT02737865 Sonazoid
20 Studies of Immune Regulation in Patients With Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes Recruiting NCT00001244
21 The Impact of Sarcopenia, Body Composition and Other Biometric Parameters on the Postoperative Outcomes of Patients Undergoing Liver Resection for Different Indications Recruiting NCT03630978
22 Vascular Liver Disease Evaluation, Follow Up and Non-Invasive Diagnostics Program Recruiting NCT03717792
23 Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions Recruiting NCT03652636
24 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
25 Advanced Magnetic Resonance Technics for the Assessment of Liver Function Before and After Transjugular Intrahepatic Portosystemic Shunt Recruiting NCT03933891
26 Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection Recruiting NCT03323359
27 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903

Search NIH Clinical Center for Nodular Regenerative Hyperplasia

Sources

Genetic Tests for Nodular Regenerative Hyperplasia

About this section
Sources

Anatomical Context for Nodular Regenerative Hyperplasia

About this section

MalaCards organs/tissues related to Nodular Regenerative Hyperplasia:

41
Liver, Bone, Bone Marrow, Testes, Kidney, Spleen, Myeloid
Sources

Publications for Nodular Regenerative Hyperplasia

About this section

Articles related to Nodular Regenerative Hyperplasia:

(show top 50) (show all 587)
# Title Authors PMID Year
1
Drug-induced nodular regenerative hyperplasia. 38 6
24879987 2014
2
Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. 38 6
22554152 2012
3
Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies. 38
31429968 2019
4
Paraneoplastic nodular regenerative hyperplasia of the liver associated with placental site trophoblastic tumor. 38
31193692 2019
5
Clinicopathologic characteristics of de novo nodular regenerative hyperplasia in pediatric liver transplant. 38
31124197 2019
6
Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. 38
31094013 2019
7
Nodular Regenerative Hyperplasia: Expression Pattern of Glutamine Synthetase and a Potential Role for Hepatic Progenitor Cells. 38
31335486 2019
8
Portal Pressure in Non-Cirrhotic Portal Hypertension: To Measure or Not to Measure. 38
31318454 2019
9
The Spectrum of Hepatic Involvement in Patients With Telomere Disease. 38
30791107 2019
10
Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. 38
31203688 2019
11
Letter to the Editor: Is Nodular Regenerative Hyperplasia an Immune-Mediated Phenomenon? 38
30820967 2019
12
Porto-sinusoidal vascular disease: proposal and description of a novel entity. 38
30957754 2019
13
Novel IL2RG Mutation Causes Leaky TLOWB+NK+ SCID With Nodular Regenerative Hyperplasia and Normal IL-15 STAT5 Phosphorylation. 38
29939941 2019
14
Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report. 38
31183008 2019
15
A case of incontinentia pigmenti associated with congenital absence of portal vein system and nodular regenerative hyperplasia. 38
30328117 2019
16
Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. 38
29775790 2019
17
Mycobacterium chimaera Hepatitis: A New Disease Entity. 38
30346305 2019
18
Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. 38
30625404 2019
19
The Utility of MR Elastography to Differentiate Nodular Regenerative Hyperplasia from Cirrhosis. 38
30014488 2019
20
Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. 38
31125338 2019
21
Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver. 38
31191844 2019
22
Common Variable Immunodeficiency and Liver Involvement. 38
28785926 2018
23
Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation. 38
30273196 2018
24
Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension-The Devil Is in the Details. 38
30014586 2018
25
Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade. 38
30014512 2018
26
Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine? 38
31208633 2018
27
Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. 38
30462857 2018
28
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases. 38
30093084 2018
29
Liver atoll sign: Nodular regenerative hyperplasia. 38
30309113 2018
30
Liver atoll sign: Nodular regenerative hyperplasia. 38
30309139 2018
31
Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine? 38
30600283 2018
32
Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy. 38
30063483 2018
33
Hepatotoxicity of Inflammatory Bowel Disease Medications. 38
30036242 2018
34
Hepatic manifestations of telomere biology disorders. 38
29758336 2018
35
Hepatocellular nodules in vascular liver diseases. 38
29804132 2018
36
Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. 38
29792748 2018
37
Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. 38
29246416 2018
38
Isolated hepatic non-obstructive sinusoidal dilatation, 20-year single center experience. 38
29844855 2018
39
Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. 38
29156507 2018
40
Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis. 38
29093156 2018
41
Refractory Hepatic Hydrothorax: A Rare Complication of Systemic Sclerosis and Presinusoidal Portal Hypertension. 38
29854501 2018
42
Portal Cavernoma Mimicking Pancreatic Malignancy. 38
29516016 2018
43
Vascular tumours of the liver: a particular story. 38
30363746 2018
44
The Liver in Oncology. 38
28987257 2017
45
Imaging assessment of portal venous system: pictorial essay of normal anatomy, anatomic variants and congenital anomalies. 38
29131270 2017
46
The Almost-Normal Liver Biopsy: Presentation, Clinical Associations, and Outcome. 38
28614198 2017
47
Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment? 38
28834232 2017
48
Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. 38
28422310 2017
49
Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20-year cohort study in all Dutch liver transplant units. 38
28815029 2017
50
Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation Type Ib) With Associated Hepatocellular Carcinoma: Case Report and Literature Review. 38
28727971 2017
Sources

Variations for Nodular Regenerative Hyperplasia

About this section
Sources

Expression for Nodular Regenerative Hyperplasia

About this section
Search GEO for disease gene expression data for Nodular Regenerative Hyperplasia.
Sources

Pathways for Nodular Regenerative Hyperplasia

About this section

Pathways related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Th17 cell differentiation 37
Show member pathways
 12.21 NOTCH2 NOTCH1 JAG1
2
Wnt / Hedgehog / Notch 4
11.84 NOTCH2 NOTCH1 JAG1
3
NOTCH2 Activation and Transmission of Signal to the Nucleus 66
Show member pathways
 11.59 NOTCH2 NOTCH1 JAG1
4
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.2 PCNA NOTCH1 JAG1
5
Th2 Differentiation Pathway 65
11.14 NOTCH1 JAG1
6
Notch Signaling Pathway (sino) 67
11 NOTCH2 NOTCH1
7
Angiogenesis (CST) 4
10.97 NOTCH2 NOTCH1 JAG1 F3 EFNB2
8
Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics 61
10.86 TPMT ITPA
9
NOTCH1 regulation of human endothelial cell calcification 1
10.62 NOTCH1 JAG1
10
Canonical and Non-canonical Notch signaling 1
10.56 NOTCH2 NOTCH1 JAG1
11
Amplification and Expansion of Oncogenic Pathways as Metastatic Traits 1
10.55 NOTCH1 JAG1
Sources

GO Terms for Nodular Regenerative Hyperplasia

About this section

Biological processes related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 Notch signaling pathway GO:0007219 9.67 NOTCH2 NOTCH1 JAG1
2 animal organ morphogenesis GO:0009887 9.65 NOTCH2 JAG1 EFNB2
3 keratinocyte differentiation GO:0030216 9.61 NOTCH1 JAG1
4 hemopoiesis GO:0030097 9.6 NOTCH2 JAG1
5 negative regulation of cell differentiation GO:0045596 9.59 NOTCH1 JAG1
6 negative regulation of neuron differentiation GO:0045665 9.58 NOTCH1 JAG1
7 positive regulation of Notch signaling pathway GO:0045747 9.58 NOTCH1 JAG1
8 neuronal stem cell population maintenance GO:0097150 9.57 NOTCH1 JAG1
9 aortic valve morphogenesis GO:0003180 9.56 NOTCH1 JAG1
10 positive regulation of Ras protein signal transduction GO:0046579 9.55 NOTCH2 NOTCH1
11 cell fate determination GO:0001709 9.54 NOTCH2 JAG1
12 negative regulation of stem cell differentiation GO:2000737 9.52 NOTCH1 JAG1
13 cardiac septum morphogenesis GO:0060411 9.51 NOTCH1 JAG1
14 response to muramyl dipeptide GO:0032495 9.46 NOTCH1 JAG1
15 venous blood vessel morphogenesis GO:0048845 9.43 NOTCH1 EFNB2
16 regulation of developmental process GO:0050793 9.4 NOTCH2 NOTCH1
17 negative regulation of growth rate GO:0045967 9.37 NOTCH2 NOTCH1
18 distal tubule development GO:0072017 9.32 NOTCH1 JAG1
19 positive regulation of cardiac epithelial to mesenchymal transition GO:0062043 9.26 NOTCH1 JAG1
20 positive regulation of aorta morphogenesis GO:1903849 9.16 NOTCH1 EFNB2
21 pulmonary valve morphogenesis GO:0003184 9.13 NOTCH2 NOTCH1 JAG1
22 Notch signaling involved in heart development GO:0061314 8.8 NOTCH2 NOTCH1 JAG1

Molecular functions related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Notch binding GO:0005112 8.62 NOTCH1 JAG1
Sources

Sources for Nodular Regenerative Hyperplasia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....